ECOG-ACRIN Cancer Research Group

.@michael_lidsky of @DukeSurgOnc and @DukeCancer is leading EA2222/PUMP, a randomized phase 3 study for patients with #Colorectal liver metastases. Learn more: bit.ly/ea2222-pump cc: @CCAlliance, @FightCRC, @NCCRTnews, @LiverUSA

EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan v. standard chemotherapy in patients w/ advanced #UrothelialCancer. The trial aims to improve treatment options & guide further research. ➡️ bit.ly/ea8231-study cc: @BladderCancerUS, @WorldBladderCan

New video: @MonikaJoshimd & @PGrivasMDPhD discuss the EA8231 #ClinicalTrial, which aims to evaluate and answer the critical question of #immunotherapy (anti-PD1/L1) rechallenge in #UrothelialCancer therapy. #BladderCancer

Help potentially improve the future of #HeadAndNeckCancer treatment. Take part in clinical study EA3191 for patients with squamous cell carcinoma of the head and neck (#HNSCC) that has come back. Learn more: bit.ly/ea3191-study #HNCA

March is #MultipleMyelomaAwareness Month, a time to recognize three clinical trials that are expanding treatment options for multiple myeloma. Learn more: EAA173/DETER-SMM, bit.ly/eaa173detersmm EAA181/EQUATE, bit.ly/eaa181equate EAA241, bit.ly/EAA241

At #SSO2026 in early March, @Senthilsurgonc presented results from the phase 2 STOPGAP trial for patients with #GastricCancer. This study laid the groundwork for @eaonc's STOPGAP II, currently enrolling patients! More: bit.ly/47Bhbk1

.@immunosarc of @LurieCancer is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated #sarcomas. More here: bit.ly/EA7222 cc: @CureSarcoma

#ClinicalTrial EA6244, led by @YanaNajjarMD of @UPMCHillmanCC, is testing a less invasive treatment approach for older adults with early-stage #melanoma. Learn more: bit.ly/ea6244-study

In the #ComboMATCH Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with #cancer. Learn more: bit.ly/ComboMATCH #PrecisionMedicine #ClinicalTrial

Trial Activation: EA6244, led by @YanaNajjarMD of @UPMCHillmanCC, is a randomized phase III study of management of treatment naive primary #Melanoma in elderly patients. Learn more: bit.ly/ea6244-study

Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: bit.ly/EA4231

"Amidst the uncertainty, one thing is clear: we need a more sustainable, consistent, reliable model to fuel #CancerResearch…" Dr. Knudsen of @parkerici in the latest issue of @TheCancerLetter. Read the full guest editorial: #ResearchFunding" target="_blank" rel="nofollow noopener">bit.ly/4bt5RHV#Resear…

#Clinicaltrial EA8192 aims to find out if treatment with durvalumab and chemotherapy can improve outcomes for patients with high grade upper tract #urothelialcancer prior to nephroureterectomy. bit.ly/ea8192-trial #blcsm #bladdercancer

#ComboMATCH Treatment Trial E5, led by @kspencer725 of @Perlmutter_CC and @DocDustyD of @UWCarbone, is a randomized phase 2 study of #sotorasib with or without #panitumumab in advanced #SolidTumors. Learn more here: bit.ly/combomatch-e5 #PrecisionMedicine

Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by @kencardonaMD, aims to find out. More: bit.ly/EA7211 #leiomyosarcoma #liposarcoma cc: @EORTC @richardriedelmd

Why does #BreastCancer come back after treatment? The EA1241 #ClinicalTrial, led by @jsparano, aims to find out by evaluating tissue samples from patients who previously enrolled in TAILORx & RxPONDER. More: bit.ly/EA1241 cc: @KalinskyKevin, @RimapatelMD

#ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: bit.ly/mm1oa-ea02-stu…

Do you have newly diagnosed #Glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: bit.ly/gable-trial

#FindingsFriday: Checkpoint blockade continues to reshape #HodgkinLymphoma treatment. E4412, recently published in @BloodPortfolio, shows that adding ipilimumab to BV + nivolumab did not significantly improve CR rates; safety profiles were similar. More: bit.ly/4s3BG14

In #ClinicalTrial EA2222/PUMP, investigators are testing #PumpChemo in addition to SOC chemo versus SOC chemo alone for patients with unresectable #ColorectalCancer liver metastases. For more: bit.ly/ea2222-pump